The primary efficacy endpoint of this interventional study was to evaluate the number of
patients achieving a complete response (CR), defined as patients switching from intensive
deferasirox -DFO treatment, at any time point during the 24 months of study, to deferasirox
monotherapy based on improvement in the cardiac magnetic resonance imaging (MRI) T2* value to
>10ms, and continue to maintain their MRI T2* to values >10 msec.